Medtronic Receives Category I CPT® Code Approvals for Altaviva™ and Symplicity Spyral™ Systems
Medtronic (MDT) received Category I CPT® codes for Altaviva™ and Symplicity Spyral™ systems, effective January 2028. These codes, replacing existing Category III codes, are permanent and indicate well-established procedures with robust clinical evidence. The Altaviva™ device treats urge urinary incontinence, while the Symplicity Spyral™ system addresses uncontrolled hypertension.
How this was made
The 30-second read
Why it matters
The approval signals stronger clinical acceptance and may lead to higher utilization and better payer coverage.
Market read
First disclosure of permanent CPT codes for Medtronic's devices, potentially enhancing future revenue streams.
What to watch
Implementation lag and physician adoption rates could delay revenue impact.
Background
Medtronic announced AMA approval of Category I CPT codes, replacing prior Category III codes for two devices.
Ticker impact
Medtronic received new Category I CPT codes for its Altaviva and Symplicity Spyral systems, a first-time regulatory approval.
potential modest upside as reimbursement expectations improve
New permanent coding can enhance payer coverage, but impact will materialize over years starting 2028.
Market effects
May boost outlook for medical device companies focused on urology and hypertension treatments.
Limited to U.S. healthcare reimbursement landscape.
Modest, primarily affecting Medtronic and peers in the medtech sector.
Counterpoint
Reimbursement improvements may be offset by competitive pressures and payer cost controls.
Key entities
- CompanyMedtronic plc
Global medical device manufacturer.
- Regulatory BodyAmerican Medical Association (AMA)
Sets CPT coding standards for medical procedures.
